617 related articles for article (PubMed ID: 10667586)
21. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
22. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.
Halaban R; Rubin JS; Funasaka Y; Cobb M; Boulton T; Faletto D; Rosen E; Chan A; Yoko K; White W
Oncogene; 1992 Nov; 7(11):2195-206. PubMed ID: 1331934
[TBL] [Abstract][Full Text] [Related]
23. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
[TBL] [Abstract][Full Text] [Related]
24. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
25. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
26. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells.
Moriyama T; Kataoka H; Hamasuna R; Yoshida E; Sameshima T; Iseda T; Yokogami K; Nakano S; Koono M; Wakisaka S
Clin Exp Metastasis; 1999; 17(10):873-9. PubMed ID: 11089886
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor stimulates cell motility in cultures of the striatal progenitor cells ST14A.
Cacci E; Salani M; Anastasi S; Perroteau I; Poiana G; Biagioni S; Augusti-Tocco G
J Neurosci Res; 2003 Dec; 74(5):760-8. PubMed ID: 14635227
[TBL] [Abstract][Full Text] [Related]
30. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
[TBL] [Abstract][Full Text] [Related]
31. Multiple aspects of the phenotype of mammary epithelial cells transformed by expression of activated M-Ras depend on an autocrine mechanism mediated by hepatocyte growth factor/scatter factor.
Zhang KX; Ward KR; Schrader JW
Mol Cancer Res; 2004 Apr; 2(4):242-55. PubMed ID: 15140946
[TBL] [Abstract][Full Text] [Related]
32. The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor.
Komada M; Kitamura N
Oncogene; 1993 Sep; 8(9):2381-90. PubMed ID: 7689722
[TBL] [Abstract][Full Text] [Related]
33. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
[TBL] [Abstract][Full Text] [Related]
34. Met and hepatocyte growth factor/scatter factor expression in human gliomas.
Koochekpour S; Jeffers M; Rulong S; Taylor G; Klineberg E; Hudson EA; Resau JH; Vande Woude GF
Cancer Res; 1997 Dec; 57(23):5391-8. PubMed ID: 9393765
[TBL] [Abstract][Full Text] [Related]
35. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta.
Odekon LE; Blasi F; Rifkin DB
J Cell Physiol; 1994 Mar; 158(3):398-407. PubMed ID: 8126064
[TBL] [Abstract][Full Text] [Related]
36. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1.
Recio JA; Merlino G
Oncogene; 2002 Feb; 21(7):1000-8. PubMed ID: 11850817
[TBL] [Abstract][Full Text] [Related]
37. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
[TBL] [Abstract][Full Text] [Related]
38. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1.
Recio JA; Merlino G
Cancer Res; 2003 Apr; 63(7):1576-82. PubMed ID: 12670907
[TBL] [Abstract][Full Text] [Related]
39. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
[TBL] [Abstract][Full Text] [Related]
40. HGF/SF-met signaling in the control of branching morphogenesis and invasion.
Zhang YW; Vande Woude GF
J Cell Biochem; 2003 Feb; 88(2):408-17. PubMed ID: 12520544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]